Understanding the mechanisms of immune resistance in pancreatic and ampullary cancers is crucial for the development of suitable biomarkers and effective immunotherapeutics. Our aim was to examine the expression of the immune inhibiting molecules PD-L1, Galectin-9, HVEM, IDO and HLA-G, as well as CD81 and FoxP31 tumor infiltrating lymphocytes (TIL), in pancreatic and ampullary cancers, and to relate their individual, as well as their combined expression, to cancer survival. Tumor tissue from 224 patients with resected pancreatic (n 5 148) and ampullary (n 5 76) cancer was used to construct tissue-microarrays. Expression of immune inhibitory molecules and TIL was examined by immunohistochemistry. We show that immune inhibitory molecules are prevalently expressed. Moreover, high tumor expression of PD-L1 (p 5 0.002), Gal-9 (p 5 0.003), HVEM (p 5 0.001), IDO (p 5 0.049), HLA-G (p 5 0.004) and high CD8/FoxP3 TIL ratio (p 5 0.006) were associated with improved cancer-specific survival. All immune biomarkers, with the exception of IDO, were individually predictive of cancer-specific survival when adjusted for clinicopathologic characteristics. For every additional immune biomarker present survival was almost two-fold prolonged (HR 0.57 95%CI 0.47-0.69, p < 0.0001). When patients with pancreatic and ampullary cancer were analyzed separately the results were similar. We conclude that pancreas and ampullary cancers are rich in expression of immuneinhibitory molecules. These molecules can be targets for future immunotherapeutics, as well as form powerful immunological biomarkers. We propose that such immune biomarker panels be included in future prospective immunotherapy trials.
Pancreatic cancer is a leading cause of cancer related death and >260,000 people die of the disease, every year, worldwide. 1 Due to its aggressive nature and late presentation 5-year survival is a dismal 6%. Only 15-20% of patients are candidates for surgical resection with the 5-year survival, in these patients, improving to 22%. Traditional chemotherapy is minimally effective, despite some recent success. 2, 3 Thus, novel therapeutic strategies against pancreatic cancer are needed.
The recognition of the critical importance of the immune system in cancer surveillance and elimination 4 has led to the development of various immunotherapeutic strategies against cancer. 5 Immune checkpoint inhibitors, such as antibodies against CTLA-4 or PD-1, have been the most successful to date. 6 These so-called immune checkpoint inhibitors interrupt immune resistance mechanisms exploited by tumors to evade natural anti-tumor immunity. Reported immune resistance mechanisms include, among others, the expression of molecules that suppress intra-tumoral T-cell responses, by ligating inhibitory receptors on T cells, such as PD-L1, galectin-9, HVEM or HLA-G and the expression of enzymes that generate T-cell inhibitory metabolites, such as IDO. The tumor microenvironment of pancreatic cancer is rich in such immune suppressive mechanisms. interaction can reinvigorate tumor-specific T-cell responses. Galectin-9 (Gal-9) is involved in T-cell homeostasis 9 by either binding to TIM-3 expressed on activated T cells and causing T cell dysfunction and apoptosis 10 or by binding to CD44 promoting T-regulatory cell differentiation. 11 Conversely, Gal-9 can also enhance T-helper 1 type antitumor immunity 12 and exert anti-metastatic potential on tumor cells. 13, 14 HVEM is a "molecular switch" with dual stimulatory and inhibitory functions, although its inhibitory function is likely dominant. 15 Binding of HVEM to BTLA or CD160, members of the immunoglobulin (Ig) superfamily, leads to inhibition of T-cells. 16 IDO is the rate limiting enzyme in the catabolism of the essential amino-acid tryptophan. Tryptophan depletion, as well as accumulation of tryptophan catabolites such as kynurenine, induce T-cell anergy and apoptosis, while IDO inhibition enhances proliferation of tumor infiltrating lymphocytes (TIL) and decreases Tregulatory cells. 17 IDO inhibitors are currently in clinical development. Finally, HLA-G is a nonclassical MHC class I molecule with a role primarily in preventing fetal rejection in pregnancy. 18 HLA-G is known to induce, upon ligation of inhibitory receptors such as ILT-2 and ILT-4, inhibition of NK cells, CD4
1 and CD8 1 lymphocytes. 19 As clinical efficacy of immune checkpoint antibodies seems partially dependent on expression of their target molecules in tumors 20, 21 immunological biomarkers will likely become extremely useful as prognostic and/or predictive tools in the future. However, given the complexity of cancer, and that of the immune system, it is unlikely that a single biomarker, like PD-L1 for example, will be able to discriminate prognostically, or predict success to therapy, in a clinically useful manner. In fact, the role of PD-L1 as a single biomarker predicting efficacy of anti-PD-1 and anti-PD-L1 therapies has come into question. Thus, the primary aim of the present study was to examine the expression and coexpression of multiple immune inhibitory molecules in pancreatic and ampullary cancer and relate their expression to the TIL, baseline known adverse clinicopathologic factors and outcome. We hypothesized that the expression of combinations of these immune inhibitory molecules would create a strong immune biomarker panel. The molecules chosen for study (PD-L1, Gal-9, HVEM, IDO and HLA-G) were chosen because their mechanism of interaction with the immune system is generally known and because a reliable primary antibody is available.
Material and Methods

Patient population and tissue samples
Archived formalin fixed paraffin-embedded (FFPE) tissue from 224 patients who underwent pancreatic cancer (n 5 148) or ampullary cancer (n 5 76) resection at the Erasmus University Medical Center Cancer Institute between December of 2000 and December 2014 were retrieved from the pathological archive. Supporting Information Table S1 lists the exact histological diagnosis and precise anatomic location for each cancer. Baseline clinicopathologic characteristics and information on the use of chemotherapy, cancer recurrence and patient survival was retrospectively collected from the electronic record. The rational for including both patients with pancreatic and ampullary cancer in our study was that cancers arising from the ampulla of Vater are frequently clinically indistinguishable from, and often treated similarly with, cancers arising from the pancreas. Patients with duodenal and extrahepatic bile duct carcinomas, as well as all endocrine neoplasms were excluded. In addition, we excluded patients who died from postoperative complications. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Medical Ethical Committee of Erasmus MC.
TMA construction
Five 1-mm cores were taken from the tumorous area of 224 patients. The tumorous areas were marked by an experienced pathologist (KB) using archived H&E glass slides. The TMAs were made using an automated tissue-arrayer ATA-27 (Beecher Instruments, Silver Springs MD). To ensure that the stainings observed in the TMA cores were representative of the entire tumor, 10 tissue blocks were chosen from which full slides were cut and stained. The purpose was to compare the findings between the TMA cores and the full slides and assess if staining heterogeneity, which might result in underestimation of immune-inhibitory molecule expression in TMAs, was an issue.
Immunohistochemistry
Immunohistochemistry was performed as previously described 22, 23 (see also supplementary methods section). Complete information on the primary antibodies used can be found in Supporting Information Table S2 . For PD-L1 staining we used a validated anti-PD-L1 antibody (clone 9A11), and a subset of cores was stained with a second validated anti-PD-L1 antibody (clone
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5H1
). Stainings of appropriate control tissues to evaluate the specificity of all antibodies can be found in Supporting Information Figure S1 .
Evaluation of immunohistochemistry staining
Scoring focused on expression on cancer cells while expression on dysplastic, atypical or normal cells or TIL was noted but not scored. Figure 1 shows typical staining patterns, and respected scores, given for all molecules under study. Scoring was performed by two independent investigators (KS and KY) blinded to clinical outcome, and differences resolved by mutual agreement. Staining intensity was scored, for each core, from a scale of 0-3 and the proportion of positive cells was determined, for each core, in quadrilles. A composite score was given from a scale from 0-3 which reflected the cytoplasmatic staining intensity (scale 0-3) multiplied by the proportion of positive cells (0-100%) for the cases where focal expression was seen. For example, if the staining intensity was 12 but the staining was only present in 50% of tumor cells then the composite score was 1. When membranous staining was detected this was separately scored using the same methodology. Average scores from the five tumor cores were used for analysis. For CD8 and FoxP3 the positive cells per core were counted manually and average counts were used for analysis.
Cutoff values
Cutoffs were optimized to produce the most discriminating biomarkers for cancer-specific survival, as further discussed in the statistical methods. For PD-L1 and IDO, where very little intracore or intercore heterogeneity was observed, only the intensity of cytoplasmatic staining was taken into consideration. IDO was considered high when the intensity score was 12 or stronger while PD-L1 was considered high when the intensity score was 11 or stronger ( Fig. 1) . For HVEM and Gal-9 intracore heterogeneity was observed, thus composite scores, including intensity and proportion of positive tumor cells, were calculated. Optimal cutoff values for cytoplasmatic HVEM staining was 1.7 (out of 3) and for Gal-9, it was 0.4 (out of 3). For HLA-G, we detected staining in only 14.6% of cases, thus any case with positive staining was considered high and all negative cases were considered low. Finally, the most optimal cutoffs for CD8 was 142 TILs per core, for FoxP3 was 25 TILs per core and for the CD8/FoxP3 ratio a ratio of 6.5.
PCR amplification
PCR amplification was performed on fresh frozen tissues from 22 patients in our study. All primers for the target genes were intron spanning. The RT-PCR amplification technique, the primer sequences and the primer sources were as previously described. 23 
Statistical analysis
All analysis was performed in duplicate. Survival curves were estimated by the Kaplan-Meier method. Cancer-specific survival and recurrence-free survival were calculated from the date of surgery to the date of event (death from cancer or recurrence of cancer respectively). In case of no event, patients were censored at date of last follow-up. The log-rank test was used to evaluate differences between survival curves of different groups. Optimal high versus low values were established by examining a grid of cutoffs and choosing the cutoff with the lowest 22 log likelihood. For multivariate analysis, the Cox proportional Hazard regression analysis was used with backward variable selection. Patients with missing values for the covariates of interest were excluded from the statistical analysis. The associations between clinicopathologic parameters, or the mRNA expressions, with the immunohistochemical expression of the immune inhibitory molecules, as well as the immunohistochemical coexpression of the immune inhibiting molecules with each other, were examined using the v 2 tests or the t test as appropriate. For these associations, a Bonferroni correction was applied to the p-values (0.05/8 immune biomarkers 5 0.0063 for statistical significance). Internal validation was performed by generating 1,000 bootstrapped datasets. Sensitivity analysis was performed by excluding the patients who received neo-adjuvant treatment (n 5 4). In addition, further sensitivity analysis was performed by examining our findings between the a priori division of patients with cancers originating at the pancreas versus ampullary region. The statistical analysis was performed using the SPSS V C 21 software.
Results
Patients and baseline clinicopathologic characteristics
Median survival was 17.5 months and median time to recurrence was 13.5 months. Baseline clinicopathologic characteristics can be seen in Table 1 . The univariate hazard ratios for all the baseline clinicopathologic characteristics can be seen in Table 2 , while the respective Kaplan-Meier curves are depicted in Figure 2a . Similar associations with time to recurrence are shown in Supporting Information Table S3 (univariate hazard ratios) and Supporting Information Figure S2a respectively (Kaplan-Meier curves). In multivariate analysis of the clinicopathologic characteristics (Table 3) margin status, lymph node status, tumor grade and preoperative CA-19.9 level were independent predictors of cancer-specific survival, while T stage, tumor location (pancreas vs. ampullary), use of systemic chemotherapy and age were not independent predictors of cancer-specific survival. Optimal cutoffs were a score of 11 or stronger for PD-L1 and a score of 12 or stronger for IDO. For Gal-9 and HVEM there was significant variability in the % of positive tumor cells thus both staining intensity and % of positive tumor cells was scored (pictures provided demonstrate this variability for Gal-9 only; red circled areas and arrows point to negatively stained tumor cells). Optimal cutoffs were a composite score of 0.4 (out of 3) for Gal-9 and a composite score of 1.7 (out of 3) for HVEM. For HLA-G relatively few cases showed expression at any level, thus any level of staining was considered positive. For CD8 and FoxP3 the numbers of positive cells were manually counted and averaged over the 5 tumor cores. Optimal cutoffs were for CD8: 142 TILs per core, for FoxP3: 25 TILs per core and for the CD8/FoxP3 ratio, a ratio of 6.5. Please also refer to the methods section for more information.
Description of immune inhibitory molecule expression
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number per tumor core was 116 (range 6-550) and median FoxP3 1 TIL number per tumor core was 25 (range 0-136).
Supporting Information Figure S3 shows the comparison between the two anti-PD-L1 antibodies (9A11 and 5H1), which was performed for selected cases. While the 5H1 antibody exhibited less intense staining, all positive cases with the 9A11 antibody were also positive with the 5H1 antibody, while all negative cases were negative with both antibodies without exception. Supporting Information Figure S4 shows the expression of the immune inhibitory molecules in the TMA cores in comparison to their representative full section slides. This was done for a total of 10 cases (four pairwise cases per antibody are shown). The expression patterns of all molecules in the TMA cores and their representative full slides were identical.
Associations of immune inhibitory molecule expression and TIL infiltration with clinicopathologic characteristics
Cutoffs were optimized to produce the most discriminating biomarkers for cancer-specific survival and they are presented in the methods section. Numbers of patients above and below these cut-offs are shown in the Kaplan-Mayer curves of Figure 2b . After Bonferroni correction it was found that high PD-L1 expression was associated with lower CA-19.9
(p < 0.001) and lower T-stage (p 5 0.002), high Gal-9 was associated with lower tumor grade (p 5 0.004), high HLA-G was associated with peri-neural invasion (p 5 0.001) and high CD8 1 TIL was associated with lower T-stage (p < 001). In addition, PD-L1 expression was positively correlated with Gal-9 (p < 0.001), Gal-9 expression was positively correlated the CD8/FoxP3 ratio (p 5 0.005) and HLA-G expression was positively correlated with HVEM (p < 0.001). Another notable association was between high PD-L1 and high CD8 1 TIL (p 5 0.028), which, despite not meeting the Bonferroni correction cutoff for significance, was nevertheless an a priory hypothesis. 24 Associations of immune inhibitory molecule expression and TIL with survival and recurrence Figure 2b shows the Kaplan-Meier curves for overall survival in relation to the optimized cut-offs of the immune inhibitory molecules and TIL under study and Table 2 shows the respected univariate hazard ratios. High cytoplasmatic expression levels of PD-L1, Gal-9, HVEM, IDO, and HLA-G as well as high CD8
1 TIL and FoxP3 1 TIL infiltration were associated with improved cancer-specific survival. Furthermore, an a priori hypothesis was that the ratio of CD8
1
TIL to FoxP3
1 TIL infiltration would predict better survival. Indeed, high CD8/FoxP3 ratio was associated with improved cancerspecific cancer survival (Fig. 2b , Table 2 ). The results were 
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similar for time to cancer recurrence (Kaplan-Meier curves in Supporting Information Figure S2b , univariate hazard ratios in Supporting Information Table S3 ).
Multivariate analysis
We first examined the individual performance of each immune inhibitory molecule and TIL parameter adjusting for all the baseline clinicopathologic characteristics (Table 4) . PD-L1, Gal-9, HVEM and the CD8/FoxP3-TIL ratio were each independent predictors of cancer-specific survival, while HLA-G showed a strong statistical trend. IDO, CD8 1 TIL and FoxP3 1 TIL were not independent predictors of cancerspecific survival. We then investigated, in multivariate analysis, how all tested immune biomarkers and clinicopathologic characteristics behaved together in order to examine if the immune biomarkers were independent of each other (Table  5 ). Margin status, lymph node status, tumor grade, Gal-9, HVEM and CD8/FoxP3 ratio remained independent predictors of cancer-specific survival while PD-L1 (p 5 0.062), and to a lesser degree HLA-G (p 5 0.125), showed a trend toward such independence. IDO expression, age, systemic chemotherapy, T-stage, CA-19.9 and tumor location were not independent predictors of cancer-specific survival.
Coexpression patterns and survival
Given the independent prognostic nature of the tested immune biomarkers, we investigated whether we could develop an even more informative predictive immunohistochemical biomarker panel. We chose to combine the immune biomarkers with the strongest prognostic ability, namely PD-L1, Gal-9, HVEM and the CD8/FoxP3-TIL ratio. Figure 2c (left panel), shows the Kaplan-Meier curve of the combined immune biomarker in relation to cancer-specific survival (HR 0.57 95%CI 0.47-0.69, p < 0.0001). In Figure 2c (right panel), we contrasted these findings with the combined presence of the independently prognostic clinicopathologic characteristics, namely margin status, lymph node status, tumor differentiation and CA-19.9 (HR 2.08 95%CI 1.74-2.47, p < 0.0001). The ability of the immune biomarkers to prognosticate patients with resected pancreatic and ampullary cancers is comparable to the prognostication ability of known clinicopathologic characteristics.
Validation
To internally validate our final results 1,000 bootstrapped datasets were generated. The combined immune biomarker remained significant during validation (HR 0.58 95%CI 0.47- 
TIL and FoXP3
1 TIL were not individually included in the analysis due to the obvious interaction with the CD8/FoxP3 ratio and because they are not independent in Table 4 .
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0.73, p < 0.0001). Sensitivity analysis performed by excluding the patients who received neo-adjuvant therapy (n 5 4) did not significantly affect any of the univariate or multivariate analysis in our study. In addition, further sensitivity analysis was performed in the subgroups of cancers arising from the pancreas versus the ampullary region. Firstly, when looking into the individual immune biomarkers (Supporting Information Table S4 ) it is apparent that the hazard ratio of each independent immune biomarker (PD-L1, Gal-9, HVEM and CD8/FoxP3 ratio) has comparable magnitude and the same direction in the pancreatic and ampullary cancer cohorts. Moreover, the hazard ratio of the combined immune biomarker for patients with pancreatic cancer was 0.62 (95%CI 0.48-0.79, p < 0.0001) and for patients with ampullary cancer was 0.52 (95%CI 0.37-0.72, p < 0.0001), thus of comparable magnitude and direction.
Comparison between immunohistochemical and mRNA expression
For 22 cases, RT-PCR was performed on fresh frozen tissues to evaluate the correlation between immunohistochemical and mRNA expression. For this experiment, only cases with high or low expression of the immune inhibitory molecules PD-L1, Gal-9 and HVEM were used with an aim to compare if there is a correlation between extremes cases. We found no correlation between cancer cell immunohistochemical and tissue mRNA expression for the three molecules examined. Box plots representing the comparisons can be seen in Supporting Information Figure S5 .
Discussion
Pancreas cancer is one of the deadliest cancers known and therapeutic advances have been slow. We show, here, that multiple immune inhibitory molecules are expressed by pancreas and ampullary cancer cells and these molecules can, in principal, become interesting targets for immunotherapy. This is especially the case for PD-L1, Gal-9 and HVEM, and their respective receptors on immune cells, namely PD-1, TIM-3 and BTLA. Antibodies targeting these interactions are already in clinical practice for other cancer types, 6 or are in preclinical and clinical development. 25 These immune inhibitory molecules have hardly been studied in relation to pancreatic cancer survival before. IDO has been shown to indeed be expressed in pancreas cancer, in 2 small studies, 26, 27 however, the relationship of IDO expression to survival was not examined. PD-L1 expression and survival has been investigated in 2 small studies of 40 and 81 patients, respectively, 28, 29 while HLA-G expression has been examined in 3 studies, 2 of which have examined a relationship to survival (122 and 158 patients). [30] [31] [32] Gal-9 and HVEM expression have never been studied in relation pancreatic cancer survival before.
We show that high expression of immune-inhibitory molecules and TIL counts are associated with better cancerspecific survival. However, while both high CD8
1 TIL and FoxP3 1 TIL counts are associated with better survival, it is only the CD8/FoxP3 ratio that is an independent predictor of cancer-specific survival. In fact, a low CD8/FoxP3 ratio is one of the strongest independent predictors of cancer death in our study. One may question why a high level of FoxP3 1 TIL would be associated with better survival, since FoxP3 1 lymphocytes are known to be immunosuppressive and aid in cancer progression. 7 In fact, this same observation has been made in colorectal cancer. 33 One explanation is that FoxP3 1 regulatory T cells are recruited into tumors as a consequence of CD81 T cell infiltration. 34 Thus, the presence of a FoxP3
1 infiltrate in a tumor simply signifies the concurrent presence of an active infiltrate of CD8 1 TIL. It is only when the FoxP3 1 TIL dominate that the prognosis becomes poor. A similar argument can be made as to why high expression of PD-L1, Gal-9, HVEM and HLA-G are, counterintuitively, associated with better survival. One hypothesis is that their expression, especially the simultaneous expression of multiple molecules, is a signal of an active immunologic attack that is beneficial to patients with cancer. This phenomenon, called adaptive immune resistance, where immune inhibitory molecules are known to become overexpressed on cancer cells in response to IFN-g and TIL infiltration, has been well described recently. 24, [34] [35] [36] The positive correlation between PD-L1 (p 5 0.028) and HLA-G (p 5 0.047) expression with numbers of CD81 TIL and the positive correlation of Gal-9 (p 5 0.005) expression with the CD8/FoxP3 ratio in our study supports the idea that expression of these molecules on pancreatic and ampullary cancer cells may be related to this phenomenon.
However, it may be that in some patients expression of PD-L1, or other immune inhibitory molecules, does not always reflect adaptive immune resistance. For example, while PD-L1 expression in the presence of TILs may signify adaptive immune resistance, expression of PD-L1 in the absence TILs may signify intrinsic induction of PD-L1. Furthermore, absence of PD-L1 in the setting of TILs may indicate immune tolerance to the tumor or the presence of molecular suppressors of PD-L1, while absence of PD-L1 in the context of low TIL count is likely to indicate immune ignorance. Such a contextual model for PD-L1 expression has already been suggested by Teng et al. 37 Basically, the prognostic role of molecules, such as PD-L1, can be influenced by the presence and activity of TILs and this may in turn explain some of the discrepancies observed in the literature regarding the prognostic role of PD-L1 in cancer.
Interestingly, the prior studies on PD-L1 and HLA-G expression in pancreatic cancer have suggested results opposite to ours; namely that high PD-L1 or high HLA-G expression are associated with poor survival. [28] [29] [30] [31] One possible explanation for the differences is the scoring techniques used. While we focused our scoring on cancer cells, the study by Wang et al. 29 used imaging software to examine total PD-L1 expression. This may include expression by stroma cells, TILs and especially expression on noncancerous cells with atypia, which could certainly give different results. In our study, we
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observed PD-L1 staining in non-neoplastic cells but were careful to include only neoplastic tissue in the TMAs and scored only expression on tumor cells and not on stromal cells or immune cells. The respected photographs of PD-L1 expression in the Wang et al. 29 study, but also in the Nomi et al. study 28 (Figs. 1b and 1a in the respective publications) certainly raise the possibility of having included nontumorous, atypical cells in the scoring methodology of these studies. Another explanation for the differences could be the use of nonvalidated antibodies. Both prior studies in pancreas cancer 28, 29 have used the MIH1 anti-PD-L1 clone for immunohistochemistry and in one of these studies the MIH1 clone was used on FFPE tissue. 29 This clone has been shown in multiple studies to not perform well on FFPE tissues when compared with other validated antibodies. 38, 39 The PD-L1 antibodies we used have been well validated for immunohistochemistry on FFPE tissues. 22, 40 In the case of HLA-G, one prior study 32 used clone 4H84 which has been shown to be nonspecific in binding its intended target, 41, 42 a second study used a polyclonal antibody, 31 while the third study did not provide the specific antibody clone used. 30 Again, we used an HLA-G antibody that has been validated in previous studies. 43, 44 In addition, we provide the expected positive control staining in placenta tissue for both PD-L1 and HLA-G (Supporting Information Figure S1 ), which was not provided by the above mentioned studies in either PD-L1 28, 29 or HLA-G. [30] [31] [32] Finally, a study by Birnbaum et al., 45 examined PD-L1 mRNA expression and found that the 19% of patients who overexpressed PD-L1 had a worse survival, results which seem opposite to ours. However, in the Birnbaum et al. study, overexpression was defined by comparing tumor levels to "normal pancreas" levels of PD-L1 mRNA. The data were obtained from 9 publicly available datasets, which included a mixture of mRNA data from adjacent tumor-free tissues and from pancreatic tissue samples obtained from pancreatic resections for other diseases, to define expression in "normal" pancreas tissue. Since normal and peri-tumoral pancreas tissue can express PD-L1 46 and since we have not compared our findings to PD-L1 expression in peri-tumoral or normal pancreas, comparison between our studies is not directly possible. In addition, the gene expression profiles in the Birnbaum et al., study have quantified mRNA from both epithelial and stromal cells, while we have focused our scoring on cancer cells only. While expression of the molecules under study was frequently observed in the tumor stroma of our patients, we have only focused our scoring on the tumor cell expression of these molecules. To highlight the differences between the two techniques we undertook the additional step of evaluating if tumor cell immunohistochemical expression of PD-L1, Gal-9 and HVEM correlates with fresh frozen tissue mRNA expression in a subset of patients. We did not find such a correlation (Supporting Information Figure S5) . This means that comparison of studies using RT-PCR to studies using immunohistochemistry, especially if immunohistochemical evaluation focuses on a specific subset of cells in the tumor microenvironment, should be done with caution.
We show that the expression of these immune inhibitory molecules can, in combination, form clinically relevant biomarkers. The independent nature of these immune biomarkers means that they influence prognosis irrespective of traditional clinicopathologic characteristics, such as lymph node metastasis or margin status. In our cohort, while every additional independent adverse clinicopathologic characteristic doubled the risk of cancer death, the presence of high levels of each additional immune biomarker reduced that risk to nearly half. This indicates the potential of our immune biomarker panel to aid in the prognostication of patients with pancreatic and ampullary cancers. While further standardization of the staining techniques is required for clinical development, tumor tissue from resected patients is readily available and immunohistochemistry is a standard, cost effective, clinical laboratory technique.
PD-L1 expression has already emerged as a biomarker of response to anti-PD-1 antibodies. 6 However, PD-L1, as a single biomarker, is not perfect. In melanoma, anywhere from 6-41% of patients who are considered PD-L1 negative do actually respond to anti-PD-1 antibodies, while half or more of the patients considered to be PD-L1 positive, do not respond. 47 It is likely that a broader immune biomarker panel, one which takes into consideration multiple immune inhibitory molecules, as well as the immune lymphocytic infiltrate, would lead to improved prediction of the patients likely to benefit from immune checkpoint inhibitors. Thus, we propose incorporation of such biomarker panels in prospective immunotherapy clinical trials.
In addition, in the case of PD-L1, an ongoing issue is the proper histological evaluation of PD-L1 expression. Both cytoplasmatic and membranous PD-L1 staining have been observed in various cancers before 24, 48, 49 and we, in our study, observed predominately cytoplasmatic staining. It has recently been hypothesized that cytoplasmatic tumor staining represents intracellular stores of PD-L1 ready to be transported to the membrane upon contact with immune cells. 24 In fact this phenomenon is well demonstrated for another immune inhibitory molecule expressed on T-cells, namely CTLA-4.
50,51
While debate is ongoing, as to the respective importance of cytoplasmatic versus membranous PD-L1 staining in the various cancer types, 24 it is likely that cytoplasmatic PD-L1 expression is biologically important and should not be ignored.
We show that the prognostic values of the expression of the independent immune biomarkers do not substantially differ between pancreatic and ampullary cancers (Supporting Information Table S4 ). In addition, in multivariate analysis, the hazard ratios for the combined immune biomarker (PD-L1, Gal-9, HVEM and CD8/FoxP3 ratio) are of similar magnitude and direction in the pancreatic and ampullary cohorts. Thus, our results are not cancer specific. In addition, tumor location (pancreas vs. ampulla) is not an independent predictor of cancer-specific survival (Table 3) or cancer recurrence (Supporting Information Table S3 ). Thus, it does not appear that cancers arising from the ampulla behave biologically different than cancers arising from the pancreas, when correcting for adverse clinicopathologic factors. However, we cannot generalize our findings to a broader definition of peri-ampullary tumors, which frequently include duodenal cancers and distal cholangiocarcinomas, since we have excluded these tumors from our cohort. As a result, while our study provides information on the immunologic profile of ampullary cancers, a type of cancer that rarely attracts research attention, further work is needed to immunologically characterize all different kinds of peri-ampullary tumors.
Our study has several strengths. This is the first study to examine the relationship of the expression of Gal-9 and IDO with survival in pancreatic and ampullary cancer and the largest study to, similarly, examine the expression of PD-L1 and HLA-G. In addition, the examination of multiple immune biomarkers in a single, large, homogeneous cohort is a novel approach, which allows for evaluating the interactions between these biomarkers. Furthermore, the size of our cohort allowed for confident internal validation of our main results by bootstrapping. This method has been shown to be the preferred internal validation method of such datasets. 52 Additional strengths are the successful use of TMAs in our study. We used five 1-mm cores to construct our TMAs, which resulted in a substantial amount of cancer cells to evaluate. This is despite the fact that pancreas cancer is generally associated with significant amounts of stroma tissue. We also show that expression of these molecules in full slides were in complete agreement with our TMA findings (Supporting Information Figure S4) . Thus, the use of TMAs in assessing tumor expression patterns of these molecules, in pancreas cancer, is possible.
However, our study has also limitations. We had limited potential to systematically examine the surrounding peritumoral tissue. While general observations could be made, we were not able to systematically examine the non-neoplastic cells. In addition, our choice of immune biomarkers studied is not exhaustive. As our understanding of tumor immunology improves, additional molecules may become interesting to study.
In conclusion, pancreas and ampulary cancers are rich in expression of immune inhibitory molecules. High cancer cell expression of PD-L1, Gal-9, HVEM and HLA-G, and high CD8/FoxP3 TIL ratio are associated with improved cancerspecific survival. The combination of such immune biomarkers can be a powerful prognostication tool for these patients. Such panels of immune biomarkers should be considered for inclusion in future immunotherapy clinical trials.
